Published in Immunotherapy on July 01, 2010
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) (BLISS-52) | NCT00424476
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (BLISS-76) | NCT00410384
Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) | NCT00657007
A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus | NCT00541749
Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum (2013) 2.06
Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther (2012) 1.33
Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol (2011) 1.16
Role of toll-like receptor 4 on lupus lung injury and atherosclerosis in LPS-challenge ApoE⁻/⁻ mice. Clin Dev Immunol (2013) 0.82
Antidotes, antibody-mediated immunity and the future of pharmaceutical product development. Hum Vaccin Immunother (2013) 0.80
Biological therapy in systemic lupus erythematosus. Int J Rheumatol (2012) 0.80
Novel transcriptional regulation of VEGF in inflammatory processes. J Cell Mol Med (2013) 0.78
Novel regulation of CCL2 gene expression by murine LITAF and STAT6B. PLoS One (2011) 0.77
Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases. Clin Dev Immunol (2011) 0.75
Drugs in early clinical development for Systemic Lupus Erythematosus. Expert Opin Investig Drugs (2016) 0.75
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A (2003) 11.65
DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol (2002) 6.85
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum (2000) 6.46
Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet (2002) 4.68
Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med (2000) 4.06
Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature (1988) 3.46
Regulation of the T-independent humoral response by TACI. Immunity (2001) 3.43
TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity (2001) 3.43
In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med (1987) 2.93
Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med (1995) 2.89
Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus (2000) 2.81
Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med (1994) 2.71
Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest (1998) 2.60
B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol (2004) 2.54
Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity (2003) 2.51
Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum (2006) 2.50
B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum (2003) 2.47
G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med (2003) 2.31
Human Genome Sciences trial data wow lupus community. Nat Biotechnol (2009) 2.17
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest (2009) 2.11
Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant (2005) 1.89
Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum (2010) 1.86
Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum (2000) 1.84
IL-10 regulates murine lupus. J Immunol (2002) 1.70
Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J Immunol (1989) 1.65
Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus (1995) 1.63
Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest (1994) 1.56
Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum (2004) 1.51
Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol (1996) 1.42
Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum (2003) 1.41
Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc. J Clin Invest (2000) 1.40
Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol (1997) 1.32
Interleukin-6 receptor blockage ameliorates murine lupus nephritis. J Am Soc Nephrol (1993) 1.24
Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch (1994) 1.17
Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis (2004) 1.13
Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (Oxford) (2003) 1.11
Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum (2007) 1.10
Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum (1997) 1.09
Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum (2003) 1.02
Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. Blood (2006) 1.02
Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. Blood (2007) 1.01
Inhibition of superantigen-induced proinflammatory cytokine production and inflammatory arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha. J Immunol (1996) 1.01
Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis. Kidney Int Suppl (1993) 1.01
Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol (1995) 0.99
SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res Ther (2003) 0.97
Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms. Kidney Int (1995) 0.97
Cytokine concentration in serum of lupus erythematosus patients: the effect on acute phase response. J Med (1997) 0.95
Dichotomic effects of IFN-gamma on the development of systemic lupus erythematosus-like syndrome in MRL-lpr / lpr mice. Eur J Immunol (2000) 0.93
Established murine lupus nephritis does not respond to exogenous interleukin-1 receptor antagonist; a role for the endogenous molecule? Immunopharmacology (1995) 0.93
Association of interleukin 6 release from endothelial cells and pulmonary hypertension in SLE. J Rheumatol (1997) 0.91
Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br J Rheumatol (1997) 0.89
Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Enhanced production by monocytes and correlation with disease activity. Arthritis Rheum (1995) 0.88
SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res Ther (2003) 0.86
Decreased production of interleukin-12 and interferon-gamma is associated with renal involvement in systemic lupus erythematosus. Scand J Rheumatol (2001) 0.85
Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus. Mod Rheumatol (2007) 0.80
Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator. Drugs R D (2008) 0.80
Update on emerging drug therapies for systemic lupus erythematosus. Expert Opin Emerg Drugs (2010) 0.77